Patients undergoing therapy with ERBITUX® (cetuximab) may have access to reimbursement through Destination Access. Destination Access is a program offered by Bristol-Myers Squibb, ImClone's partner for commercialization of ERBITUX in the U.S. and Canada.

Destination Access
Destination Access was created by Bristol-Myers Squibb to improve access to care for cancer patients receiving Bristol-Myers Squibb Oncology products and to help community-based oncology practices secure payment for patients' medicines within payer guidelines. To be considered for free Bristol-Myers Squibb products, Destination Access can also direct qualifying patients to the Bristol-Myers Squibb-AmeriCares Oncology/Virology Access Program. For more information about Destination Access, visit www.destinationaccess.com.

For more information, contact the Destination Access Program at (800) 861-0048.